Tempus, a technology company focused on helping doctors personalize cancer care, and Rush University Medical Center announced today a partnership to pursue their shared goal of providing customized treatment to cancer patients.
A leading authority on developing innovative immunotherapy treatments is Rush' new division chief of the Hematology, Oncology and Cell Therapy. Dr. Timothy Kuzel will focus on continuing to assemble multidisciplinary teams to craft individualized treatments for each patient.
While still considered rare, head and neck cancers are striking younger men at a higher and more rapid rate, and many of the patients do not have the typical cancer risk factors. Instead, the cases are resulting from a sexually transmitted virus.